The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Christopher Von Seggern net worth and biography

Christopher Von Seggern Biography and Net Worth

Insider of Xenon Pharmaceuticals

Dr. Von Seggern is employed by our wholly owned subsidiary, Xenon Pharmaceuticals USA Inc. and has served as our Chief Commercial Officer since August 2020. Most recently, prior to joining Xenon, Dr. Von Seggern was a Partner at ClearView Healthcare Partners from 2011 to 2019, where he developed broad experience overseeing a range of commercial engagements involving multiple therapeutic areas as well as strategic due diligence on in-licensing and M&A opportunities. Through his tenure from 2008 to 2019 at ClearView, Dr. Von Seggern worked across the pharmaceutical sector with emphasis in orphan diseases and transformational technologies. From 2006 to 2008, Dr. Von Seggern served as a Consultant for Leerink Swann Strategic Advisors. Dr. Von Seggern began his career at the National Institutes of Health where he served as an AAAS Science Policy Fellow within the National Institute of Diabetes, Digestive, and Kidney Diseases from 2005 to 2006. While at the NIDDK, Dr. Von Seggern helped set strategic direction for the Institute focusing on diabetes research and translational medicine. Dr. Von Seggern received his Ph.D. in pharmacology and molecular sciences as well as his Master of Public Health from Johns Hopkins University School of Medicine. Dr. Von Seggern received his MBA from Northeastern University and he earned his B.S. in biochemistry and molecular biology from the Pennsylvania State University.

How old is Christopher Von Seggern?: Dr. Von Seggern is currently 45 years old. There are 7 older executives and no younger executives at Xenon Pharmaceuticals. The oldest executive at Xenon Pharmaceuticals is Ms. Shelley McCloskey B.A., Executive Vice President of Human Resources, who is 64 years old. Learn More on Christopher Von Seggern's age.
How do I contact Christopher Von Seggern?: The corporate mailing address for Dr. Von Seggern and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Christopher Von Seggern's contact information.
Has Christopher Von Seggern been buying or selling shares of Xenon Pharmaceuticals?: Christopher Von Seggern has not been actively trading shares of Xenon Pharmaceuticals over the course of the past ninety days. Most recently, on Monday, December 6th, Seggern Christopher Von bought 4,000 shares of Xenon Pharmaceuticals stock. The stock was acquired at an average cost of $24.40 per share, with a total value of $97,600.00. Learn More on Christopher Von Seggern's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 150,698 shares worth more than $6,077,150.31. The most recent insider tranaction occured on March, 7th when EVP Sherrington Robin sold 7,137 shares worth more than $330,300.36. Insiders at Xenon Pharmaceuticals own 5.4% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 3/7/2024.

Christopher Von Seggern Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/6/2021	Buy	4,000	$24.40	$97,600.00

Christopher Von Seggern Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $40.43

$40.02

$40.43

50 Day Range

MA: $44.12

$39.50

$49.63

2 Week Range

Now: $40.43

$27.99

$50.99

Volume

2,313 shs

Average Volume

394,192 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15